An2 Therapeutics Inc (ANTX) - News Archive

In a significant advancement in the fight against tuberculosis (TB), AN2 Therapeutics, Inc., a pioneering biopharmaceutical company based in Menlo Park, California, has announced a research collaboration with the global...

Chagas disease, caused by the parasite Trypanosoma cruzi , represents a significant public health challenge affecting approximately 6 to 7 million people worldwide. This neglected tropical disease can lead to severe chr...

Melioidosis, caused by the bacterium Burkholderia pseudomallei, presents a significant public health challenge, particularly in Southeast Asia and northern Australia. Characterized by a broad clinical spectrum, ranging...

AN2 Therapeutics, a biopharmaceutical firm dedicated to developing innovative small molecule therapeutics through its proprietary boron chemistry platform, has adopted a limited duration stockholder rights plan in respo...

AN2 Therapeutics Announces Promising Results for Epetraborole in Treating MAC Lung Disease Menlo Park, Calif. AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company renowned for its pioneering efforts in the...